Advertisement

CardioVascular and Interventional Radiology

, Volume 43, Issue 2, pp 196–203 | Cite as

125I Irradiation Stent for Hepatocellular Carcinoma with Main Portal Vein Tumor Thrombosis: A Systematic Review

  • Lei Zhang
  • Bo Hu
  • Wei Li
  • Peng Huang
  • Shen Zhang
  • Bin-Yan ZhongEmail author
  • Cai-Fang NiEmail author
Review
  • 74 Downloads

Abstract

A systematic review was conducted to provide an overview of the efficacy and safety of 125I irradiation stent placement for patients with hepatocellular carcinoma (HCC) and main portal vein tumor thrombosis (MPVTT). Six studies with 406 patients were included in the final analysis. The median overall survival for patients treated with 125I irradiation stent placement was 10.3 months. The most common radiation-related adverse event was leukopenia. The stent-related adverse events consisted of fever, abdominal pain, hemorrhage, and anorexia. No stent or seed migration was reported. Overall, the use of an 125I irradiation stent has the potential to act as an alternative therapy for patients with HCC with MPVTT.

Keywords

Hepatocellular carcinoma Portal vein tumor thrombosis Radioactive stent Endovascular brachytherapy Systematic review 

Notes

Acknowledgements

None.

Funding

This study was supported by the National Natural Science Foundation of China (81901847) and the Suzhou Science and Technology Youth Plan (KJXW2018003). Funding source had no involvement in the financial support for the conduct of the research and preparation of the article.

Compliance with Ethical Standards

Conflict of interest

On behalf of all authors, the corresponding authors state that there is no conflict of interest.

Consent for Publication

For this type of study, consent for publication is not required.

Human and Animal Rights

This article does not contain any studies with human participants or animals performed by any of the authors.

Informed Consent

For this type of study, informed consent is not required.

References

  1. 1.
    Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424.  https://doi.org/10.3322/caac.21492.CrossRefGoogle Scholar
  2. 2.
    Forner A, Reig M, Bruix J. Hepatocellular carcinoma. Lancet. 2018;391(10127):1301–14.  https://doi.org/10.1016/S0140-6736(18)30010-2.CrossRefGoogle Scholar
  3. 3.
    Lee SW, Lee HL, Han NI, Kwon JH, Nam SW, Jang JW, et al. Transarterial infusion of epirubicin and cisplatin combined with systemic infusion of 5-fluorouracil versus transarterial chemoembolization using doxorubicin for unresectable hepatocellular carcinoma with portal vein tumor thrombosis: a retrospective analysis. Ther Adv Med Oncol. 2017;9(10):615–26.  https://doi.org/10.1177/1758834017728018.CrossRefPubMedPubMedCentralGoogle Scholar
  4. 4.
    Zhang ZM, Lai EC, Zhang C, Yu HW, Liu Z, Wan BJ, et al. The strategies for treating primary hepatocellular carcinoma with portal vein tumor thrombus. Int J Surg. 2015;20:8–16.  https://doi.org/10.1016/j.ijsu.2015.05.009.CrossRefPubMedGoogle Scholar
  5. 5.
    Llovet JM, Bustamante J, Castells A, Vilana R, Ayuso Mdel C, Sala M, et al. Natural history of untreated nonsurgical hepatocellular carcinoma: rationale for the design and evaluation of therapeutic trials. Hepatology. 1999;29(1):62–7.  https://doi.org/10.1002/hep.510290145.CrossRefPubMedGoogle Scholar
  6. 6.
    Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008;359(4):378–90.  https://doi.org/10.1056/NEJMoa0708857.CrossRefGoogle Scholar
  7. 7.
    Cheng AL, Kang YK, Chen Z, Tsao CJ, Qin S, Kim JS, et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol. 2009;10(1):25–34.  https://doi.org/10.1016/S1470-2045(08)70285-7.CrossRefPubMedGoogle Scholar
  8. 8.
    Bruix J, Raoul JL, Sherman M, Mazzaferro V, Bolondi L, Craxi A, et al. Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: subanalyses of a phase III trial. J Hepatol. 2012;57(4):821–9.  https://doi.org/10.1016/j.jhep.2012.06.014.CrossRefPubMedGoogle Scholar
  9. 9.
    Cheng AL, Guan Z, Chen Z, Tsao CJ, Qin S, Kim JS, et al. Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma according to baseline status: subset analyses of the phase III Sorafenib Asia-Pacific trial. Eur J Cancer. 2012;48(10):1452–65.  https://doi.org/10.1016/j.ejca.2011.12.006.CrossRefPubMedGoogle Scholar
  10. 10.
    Kokudo T, Hasegawa K, Matsuyama Y, Takayama T, Izumi N, Kadoya M, et al. Survival benefit of liver resection for hepatocellular carcinoma associated with portal vein invasion. J Hepatol. 2016;65(5):938–43.  https://doi.org/10.1016/j.jhep.2016.05.044.CrossRefPubMedGoogle Scholar
  11. 11.
    Chok KS, Cheung TT, Chan SC, Poon RT, Fan ST, Lo CM. Surgical outcomes in hepatocellular carcinoma patients with portal vein tumor thrombosis. World J Surg. 2014;38(2):490–6.  https://doi.org/10.1007/s00268-013-2290-4.CrossRefPubMedGoogle Scholar
  12. 12.
    Lee DS, Seong J. Radiotherapeutic options for hepatocellular carcinoma with portal vein tumor thrombosis. Liver Cancer. 2014;3(1):18–30.  https://doi.org/10.1159/000343855.CrossRefPubMedPubMedCentralGoogle Scholar
  13. 13.
    Inarrairaegui M, Thurston KG, Bilbao JI, D'Avola D, Rodriguez M, Arbizu J, et al. Radioembolization with use of yttrium-90 resin microspheres in patients with hepatocellular carcinoma and portal vein thrombosis. J Vasc Interv Radiol. 2010;21(8):1205–12.  https://doi.org/10.1016/j.jvir.2010.04.012.CrossRefPubMedGoogle Scholar
  14. 14.
    Vilgrain V, Pereira H, Assenat E, Guiu B, Ilonca AD, Pageaux GP, et al. Efficacy and safety of selective internal radiotherapy with yttrium-90 resin microspheres compared with sorafenib in locally advanced and inoperable hepatocellular carcinoma (SARAH): an open-label randomised controlled phase 3 trial. Lancet Oncol. 2017;18(12):1624–36.  https://doi.org/10.1016/S1470-2045(17)30683-6.CrossRefPubMedGoogle Scholar
  15. 15.
    Chow PKH, Gandhi M, Tan SB, Khin MW, Khasbazar A, Ong J, et al. SIRveNIB: selective internal radiation therapy versus Sorafenib in Asia-Pacific patients with hepatocellular carcinoma. J Clin Oncol. 2018;36(19):1913–21.  https://doi.org/10.1200/JCO.2017.76.0892.CrossRefPubMedGoogle Scholar
  16. 16.
    Yamakado K, Tanaka N, Nakatsuka A, Matsumura K, Takase K, Takeda K. Clinical efficacy of portal vein stent placement in patients with hepatocellular carcinoma invading the main portal vein. J Hepatol. 1999;30(4):660–8.CrossRefGoogle Scholar
  17. 17.
    Vibert E, Azoulay D, Cunha AS, Adam R, Samuel D, Castaing D. Portal stenting for hepatocellular carcinoma extending into the portal vein in cirrhotic patients. J Surg Oncol. 2013;107(7):696–701.  https://doi.org/10.1002/jso.23306.CrossRefPubMedGoogle Scholar
  18. 18.
    Guo JH, Teng GJ, Zhu GY, He SC, Fang W, Deng G, et al. Self-expandable esophageal stent loaded with 125I seeds: initial experience in patients with advanced esophageal cancer. Radiology. 2008;247(2):574–81.  https://doi.org/10.1148/radiol.2472070999.CrossRefPubMedGoogle Scholar
  19. 19.
    Zhu HD, Guo JH, Mao AW, Lv WF, Ji JS, Wang WH, et al. Conventional stents versus stents loaded with (125)iodine seeds for the treatment of unresectable oesophageal cancer: a multicentre, randomised phase 3 trial. Lancet Oncol. 2014;15(6):612–9.  https://doi.org/10.1016/S1470-2045(14)70131-7.CrossRefPubMedGoogle Scholar
  20. 20.
    Luo J, Yan Z, Liu Q, Qu X, Wang J. Endovascular placement of iodine-125 seed strand and stent combined with chemoembolization for treatment of hepatocellular carcinoma with tumor thrombus in main portal vein. J Vasc Interv Radiol. 2011;22(4):479–89.  https://doi.org/10.1016/j.jvir.2010.11.029.CrossRefPubMedGoogle Scholar
  21. 21.
    Lu J, Guo JH, Zhu HD, Zhu GY, Chen L, Teng GJ. Safety and efficacy of irradiation stent placement for malignant portal vein thrombus combined with transarterial chemoembolization for hepatocellular carcinoma: a single-center experience. J Vasc Interv Radiol. 2017;28(6):786–94.e3.  https://doi.org/10.1016/j.jvir.2017.02.014.CrossRefPubMedGoogle Scholar
  22. 22.
    Peng SY, Wang XA, Huang CY, Li JT, Hong DF, Wang YF, et al. Better surgical treatment method for hepatocellular carcinoma with portal vein tumor thrombus. World J Gastroenterol. 2018;24(40):4527–35.  https://doi.org/10.3748/wjg.v24.i40.4527.CrossRefPubMedPubMedCentralGoogle Scholar
  23. 23.
    Wells GA SB, O’Connell D, Peterson J, Welch V, Losos M, et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. 2015. https://www.ohri.ca/programs/clinical_epidemiology/oxford.asp.
  24. 24.
    Zhang ZH, Liu QX, Zhang W, Ma JQ, Wang JH, Luo JJ, et al. Combined endovascular brachytherapy, sorafenib, and transarterial chemobolization therapy for hepatocellular carcinoma patients with portal vein tumor thrombus. World J Gastroenterol. 2017;23(43):7735–45.  https://doi.org/10.3748/wjg.v23.i43.7735.CrossRefPubMedPubMedCentralGoogle Scholar
  25. 25.
    Yu TZ, Zhang W, Liu QX, Li WH, Ma JQ, Zhang ZH, et al. Endovascular brachytherapy combined with portal vein stenting and transarterial chemoembolization improves overall survival of hepatocellular carcinoma patients with main portal vein tumor thrombus. Oncotarget. 2017;8(7):12108–19.  https://doi.org/10.18632/oncotarget.14520.CrossRefPubMedPubMedCentralGoogle Scholar
  26. 26.
    Sun JH, Zhou T, Zhu T, Zhang Y, Nie C, Ai J, et al. Portal vein stenting combined with Iodine-125 seeds endovascular implantation followed by transcatheter arterial chemoembolization for treatment of hepatocellular carcinoma patients with portal vein tumor thrombus. Biomed Res Int. 2016;2016:3048261.  https://doi.org/10.1155/2016/3048261.CrossRefPubMedPubMedCentralGoogle Scholar
  27. 27.
    Li CX, He X, Hu BS, Li Y, Shao PJ, Yu XY, et al. Efficacy of therapy for hepatocellular carcinoma with portal vein tumor thrombus: chemoembolization and stent combined with iodine-125 seed. Cancer Biol Ther. 2011;12(10):865–71.  https://doi.org/10.4161/cbt.12.10.17676.CrossRefGoogle Scholar
  28. 28.
    Shao YY, Huang CC, Liang PC, Lin ZZ. Hepatic arterial infusion of chemotherapy for advanced hepatocellular carcinoma. Asia Pac J Clin Oncol. 2010;6(2):80–8.  https://doi.org/10.1111/j.1743-7563.2010.01287.x.CrossRefPubMedGoogle Scholar
  29. 29.
    Wang K, Guo WX, Chen MS, Mao YL, Sun BC, Shi J, et al. Multimodality treatment for hepatocellular carcinoma with portal vein tumor thrombus: a large-scale, multicenter, propensity mathching score analysis. Medicine (Baltimore). 2016;95(11):e3015.  https://doi.org/10.1097/MD.0000000000003015.CrossRefGoogle Scholar
  30. 30.
    Zhang XP, Gao YZ, Chen ZH, Chen MS, Li LQ, Wen TF, et al. An eastern hepatobiliary surgery hospital/portal vein tumor thrombus scoring system as an aid to decision making on hepatectomy for hepatocellular carcinoma patients with portal vein tumor thrombus: a multicenter study. Hepatology. 2018.  https://doi.org/10.1002/hep.30490.CrossRefPubMedPubMedCentralGoogle Scholar
  31. 31.
    Yamakado K, Nakatsuka A, Tanaka N, Fujii A, Terada N, Takeda K. Malignant portal venous obstructions treated by stent placement: significant factors affecting patency. J Vasc Interv Radiol. 2001;12(12):1407–15.CrossRefGoogle Scholar
  32. 32.
    Zhang FJ, Li CX, Jiao DC, Zhang NH, Wu PH, Duan GF, et al. CT guided 125iodine seed implantation for portal vein tumor thrombus in primary hepatocellular carcinoma. Chin Med J (Engl). 2008;121(23):2410–4.CrossRefGoogle Scholar
  33. 33.
    Zhu HD, Guo JH, Zhu GY, He SC, Fang W, Deng G, et al. A novel biliary stent loaded with (125)I seeds in patients with malignant biliary obstruction: preliminary results versus a conventional biliary stent. J Hepatol. 2012;56(5):1104–11.  https://doi.org/10.1016/j.jhep.2011.12.018.CrossRefPubMedGoogle Scholar
  34. 34.
    Zhang XB, Wang JH, Yan ZP, Qian S, Liu R. Hepatocellular carcinoma invading the main portal vein: treatment with transcatheter arterial chemoembolization and portal vein stenting. Cardiovasc Intervent Radiol. 2009;32(1):52–61.  https://doi.org/10.1007/s00270-008-9454-x.CrossRefPubMedGoogle Scholar
  35. 35.
    DeLeve LD, Valla DC, Garcia-Tsao G. American Association for the Study Liver D. Vascular disorders of the liver Hepatology. 2009;49(5):1729–64.  https://doi.org/10.1002/hep.22772.CrossRefPubMedGoogle Scholar
  36. 36.
    Basili S, Raparelli V, Violi F. The coagulopathy of chronic liver disease: is there a causal relationship with bleeding? Yes. Eur J Intern Med. 2010;21(2):62–4.  https://doi.org/10.1016/j.ejim.2010.01.005.CrossRefPubMedGoogle Scholar
  37. 37.
    Qi X, De Stefano V, Li H, Dai J, Guo X, Fan D. Anticoagulation for the treatment of portal vein thrombosis in liver cirrhosis: a systematic review and meta-analysis of observational studies. Eur J Intern Med. 2015;26(1):23–9.  https://doi.org/10.1016/j.ejim.2014.12.002.CrossRefPubMedGoogle Scholar
  38. 38.
    Loffredo L, Pastori D, Farcomeni A, Violi F. Effects of anticoagulants in patients with cirrhosis and portal vein thrombosis: a systematic review and meta-analysis. Gastroenterology. 2017;153(2):480–7e1.  https://doi.org/10.1053/j.gastro.2017.04.042.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature and the Cardiovascular and Interventional Radiological Society of Europe (CIRSE) 2019

Authors and Affiliations

  1. 1.Department of Interventional RadiologyThe First Affiliated Hospital of Soochow UniversitySuzhouChina

Personalised recommendations